S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

VNDA Vanda Pharmaceuticals Inc

4.3999

-0.3001 (-6.39%)

15 Feb 2025 - Closed

Delayed by 15 minutes

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Article too big to display. Click here to view on the SEC website

Vanda Pharmaceuticals (NASDAQ:VNDA)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Vanda Pharmaceuticals Charts.

Vanda Pharmaceuticals (NASDAQ:VNDA)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Vanda Pharmaceuticals Charts.

Vanda Pharmaceuticals Inc News

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Saturday 15 February 2025 (18 hours ago) • Edgar (US Regulatory)

Form 8-K - Current report
Friday 14 February 2025 (2 days ago) • Edgar (US Regulatory)

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
Friday 14 February 2025 (2 days ago) • PR Newswire (US)

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Saturday 8 February 2025 (1 week ago) • Edgar (US Regulatory)

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025
Thursday 6 February 2025 (1 week ago) • PR Newswire (US)

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
Monday 3 February 2025 (2 weeks ago) • GlobeNewswire Inc.

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
Monday 3 February 2025 (2 weeks ago) • PR Newswire (US)

Form 8-K - Current report
Tuesday 28 January 2025 (3 weeks ago) • Edgar (US Regulatory)

Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis
Monday 27 January 2025 (3 weeks ago) • PR Newswire (US)

Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review
Thursday 9 January 2025 (1 month ago) • PR Newswire (US)

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera
Saturday 21 December 2024 (2 months ago) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 19 November 2024 (3 months ago) • Edgar (US Regulatory)

More Vanda Pharmaceuticals Inc News Articles

Gold vs US Dollar

Commonwealth Bank Of Aus...

S&P ASX 300 Metals and M...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions